JUVAF - Juva Life Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0430
+0.0010 (+2.38%)
As of 10:07AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0420
Open0.0360
BidN/A x N/A
AskN/A x N/A
Day's Range0.0360 - 0.0430
52 Week Range0.0340 - 0.2000
Volume1,901
Avg. Volume54,070
Market Cap7.053M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateSep 06, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for JUVAF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Juva Life Begins Construction on Redwood City Retail Storefront, On Track to Open in Early 2023

    Company Was Previously the Highest-Scoring Applicant During the Permitting Process in Redwood City, CaliforniaVANCOUVER, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today that the Company has started construction on their upcoming Redwoo

  • GlobeNewswire

    Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process

    Company Reports Successful Medicinal Chemistry Effort to Scale Up Small Molecule Isolated from Cannabis Plant to Support Preclinical and Non-Clinical StudiesVANCOUVER, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today announced the successful scal

  • GlobeNewswire

    Juva Life Announces Flōs, New Branded Cannabis Flower Product Line

    New Branded Cannabis Product Line Diversifies Company Product Offerings; Compliments Pharmaceutical ResearchVANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s new product line, Flōs, a branded line of flo

  • GlobeNewswire

    Juva Life Reports 144% Increase in Revenue for Q2 2022; Schedules Webinar for 9/6/22

    Company Reports Its Q2 2022 Financial Results and Provides Comments on OperationsVANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today highlights its financial and operating results for Q2 of 2022, and announces an upcoming webinar to revie

  • GlobeNewswire

    Juva Life Launches Revised JuLi Registry, Showcases Cannabis and CBD Brands to Track Effects on Cannabis Patients

    Life Science Research and Vertically Integrated California Cultivator Creates Global Research Registry to Better Understand Clinical Effects of Cannabis VANCOUVER, British Columbia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today announced their newly revised WCG

  • GlobeNewswire

    Juva Life Highlights Q1 2022 Financials Showing 97% Increase in Revenue

    Company Reports Its Q1 2022 Results and Provides Comments on OperationsVANCOUVER, British Columbia, July 19, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today highlights its financial and operating results for Q1 of 2022. $1.16 million of revenue was generated in Q1 2022, almost

  • GlobeNewswire

    Pelorus Equity Group Closes $11.8 Million Debt Financing, Enabling Juva Life to Expand Cannabis Operations, Further Clinical Research

    NEWPORT BEACH, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Pelorus Equity Group (“Pelorus”), the leading provider of commercial real estate loans for the cannabis sector, announced it has closed an $11.8 million financing with Juva Life Inc. (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution. The primary purpose of the financing, which closed on June 15, 2022, is to finan

  • GlobeNewswire

    Juva Life Secures $11.8 Million in Financing, Enabling Expansion of Cannabis Operations, Further Clinical Research

    Cannabis and Life Sciences Company Closes $11.8 Million in Non-Dilutive Debt FinancingVANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today that it has closed a non-dilutive financing of $11.8 million, enabling the Company to acquire it